New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period

Zeposia maintains complaint control indeed in the event of temporary treatment interruption for over to eight wee

Zeposia is the first oral sphingosine 1- phosphate( S1P) receptor modulator approved to treat cases with ulcerative colitis
Bristol Myers Squibb( NYSE BMY) moment blazoned new post hoc analyses from the Phase 3 True North study assessing the duration of response following nonstop Zeposia( ozanimod) treatment for over to one time and following treatment interruption in cases with relatively to oppressively active ulcerative colitis( UC). After achieving a clinical response at the end of the induction period,86.1 of cases who remained on Zeposia showed no complaint relapse at Week 52( Kaplan- Meier( KM) estimates of no complaint relapse at Week 52 Zeposia/ Zeposia,86.1; Zeposia/ placebo,62.6).

As temporary treatment termination may do in clinical practice, these analyses estimated the duration of response following treatment interruption. Findings showed that Zeposia maintained complaint control for over to eight weeks in cases who switched to placebo after original response( KM estimates of no complaint relapse at Week 8 Zeposia/ Zeposia,96.1; Zeposia/ placebo,90.6). These analyses( donation# 62) and 10 fresh Zeposia objectifications demonstrating Bristol Myers Squibb’s robust body of exploration in gastroenterology are being presented at the American College of Gastroenterology( ACG) periodic scientific meeting, taking place October 21 – 26, 2022.
” These data presented at ACG demonstrate Zeposia treatment prevents complaint fall over one time of nonstop treatment and maintains complaint control indeed in the event of temporary interruption, ” said Jonathan Sadeh, MD, MSc, elderly vice chairman of Immunology and Fibrosis Development, Bristol Myers Squibb. “ These analyses support the established profile of Zeposia for people living with relatively to oppressively active UC and emphasize our long-standing commitment to the gastroenterology community. ”

About Ulcerative Colitis
Ulcerative colitis, a habitual seditious bowel complaint( IBD), is characterized by an irregular, habitual vulnerable response that creates inflammation and ulcers( blisters) in the mucosa( filling) of the large intestine( colon) or rectum. Symptoms include bloody droppings, severe diarrhea and frequent abdominal pain. Ulcerative colitis has a major impact on cases’ health- related quality of life, including physical functioning, social and emotional well- being and capability to go to work/ academy. numerous cases have an shy response or don’t respond at each to presently available curatives. It’s estimated that roughly12.6 million people worldwide are living with IBD.

About Zeposia( ozanimod)
Zeposia( ozanimod) is an oral, sphingosine 1- phosphate( S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. Zeposia reduces the capacity of lymphocytes to resettle from lymphoid towel, reducing the number of circulating lymphocytes in supplemental blood. The medium by which Zeposia exerts remedial goods in ulcerative colitis( UC) is unknown but may involve the reduction of lymphocyte migration into the bowel.

Bristol Myers Squibb is continuing to estimate Zeposia in the ongoing True North open- marker extension trial, designed to assess the longer- term profile of Zeposia for the treatment of relatively to oppressively active UC. The company is also probing Zeposia for the treatment of relatively to oppressively active Crohn’s complaint in the ongoing Phase 3 YELLOWSTONE clinical trial program.
TheU.S. Food and Drug Administration approved Zeposia for the treatment of grown-ups with relapsing forms of multiple sclerosis in March 2020 and grown-ups with relatively to oppressively active UC in May 2021. The European Commission approved Zeposia for the treatment of adult cases with relapsing remitting multiple sclerosis with active complaint as defined by clinical or imaging features in May 2020 and for the treatment of grown-ups with relatively to oppressively active UC who have had an shy response, lost response, or were intolerant to either conventional remedy or a birth agent in November 2021.
Bristol Myers Squibb Pioneering Paths Forward in Immunology to Transform Cases ’ Lives

Bristol Myers Squibb is inspired by a single vision – transubstantiating cases ’ lives through wisdom. For people living with vulnerable- mediated conditions, the enervating reality of enduring habitual symptoms and complaint progression can take a risk on their physical, emotional and social well- being, making simple tasks and diurnal life a challenge. Driven by our deep understanding of the vulnerable system that spans over 20 times of experience, and our passion to help cases, the company continues to pursue pathbreaking wisdom with the thing of delivering meaningful results that address unmet requirements in rheumatology, gastroenterology, dermatology and neurology. We follow the wisdom, aiming to knitter curatives to individual requirements, ameliorate issues and expand treatment options by working to identify mechanisms with the eventuality to achieve long- term absolution – and maybe indeed cures – in the future. By erecting hookups with experimenters, cases and caregivers to deliver innovative treatments, Bristol Myers Squibb strives to elevate patient care to new norms and deliver what matters most – the pledge of living a better life.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose charge is to discover, develop and deliver innovative drugs that help cases prevail over serious conditions. For further information about Bristol Myers Squibb, visit us

Source link: